LFCR

Business Context and Reporting Period

This Form 10-Q covers the fiscal quarter and six months ended November 28, 2010, for Landec Corporation (Note: The input metadata references "LIFECORE BIOMEDICAL, INC.", but the filing text identifies the registrant as Landec Corporation, which acquired Lifecore Biomedical, Inc. on April 30, 2010). Landec operates four business segments: Food Products Technology (Apio), Export, HA-based Biomaterials (Lifecore), and Technology Licensing. The company designs, develops, and sells polymer products for food, agricultural, and medical applications.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 15% for the quarter and 11% for the six-month period compared to the prior year. This growth was primarily driven by the inclusion of the newly acquired Lifecore Biomedical (HA-based Biomaterials) segment, which contributed $8.4 million in revenue for the quarter and $14.8 million for the six months.
• Profitability: Gross profit increased 60% for the quarter and 45% for the six months, largely due to the high-margin HA business. However, the Food Products Technology segment saw a 4% revenue decline and a 21% gross profit decline due to lower unit sales volumes and produce shortages caused by weather conditions.
• Operating Expenses: R&D expenses surged 139% and SG&A expenses increased 45% year-over-year, primarily attributable to the integration and operations of the Lifecore subsidiary.
• Liquidity: Cash and cash equivalents decreased significantly from $27.8 million to $5.4 million over the six-month period. This reduction was driven by the acquisition of Lifecore, capital expenditures ($3.5 million), and net purchases of marketable securities ($19.2 million).

Guidance, Outlook, and Risks

• Outlook: Management believes existing cash, cash equivalents, and marketable securities, combined with cash from operations, will be sufficient to finance operational and capital requirements for at least the next twelve months. No specific numerical guidance for future periods was provided in this filing.
• Debt Covenants: The company is in compliance with all financial covenants related to its $20 million credit agreement with Wells Fargo and its industrial revenue bonds. The credit agreement requires minimum levels of net income, quick ratio, and fixed coverage ratio.
• Key Risks:
  • Customer Concentration: The top five customers accounted for 43% of revenues for the six months ended November 28, 2010, with Costco Wholesale Corp. alone representing 15%.
  • Weather and Supply: The Food Products Technology segment is sensitive to weather conditions affecting produce supply and pricing, as evidenced by shortages in November 2010.
  • Contingent Consideration: The company may be required to pay up to an additional $10.0 million in earnout payments to Lifecore's former shareholders if specific revenue targets are met in calendar years 2011 and 2012.
• Unusual Items: The company recorded a $1.0 million impairment loss on its investment in Aesthetic Sciences Corporation in the prior fiscal year (May 30, 2010). No new impairments were recorded in the current period.

Investor Verification Checklist

• Lifecore Integration: Verify the progress of the Lifecore acquisition integration and the trajectory of its revenue contribution against the earnout targets.
• Produce Supply Chain: Monitor weather patterns and produce availability in California, as shortages directly impact the margins of the Food Products Technology segment.
• Customer Concentration: Assess the stability of relationships with top customers, particularly Costco, given they represent a significant portion of revenue.
• Debt Servicing: Review the company's ability to maintain compliance with the Wells Fargo credit agreement covenants, specifically the minimum net income and quick ratio requirements.
• Cash Position: Track the burn rate of cash and cash equivalents, which dropped by over $22 million in six months, to ensure sufficient liquidity for operations and debt payments.